Coverage for pharmacy benefit drugs is determined by whether the product is included on the payer's Drug List or has an approved exception. The plan may not cover drugs not shown on the Drug List. In addition, the plan's benefit materials note that over-the-counter equivalents, compounded medications, repackaged medications, and non–FDA‑approved drugs may not be covered; providers and members should refer to the member's specific benefit plan or call the number on the ID card for clarification or to request an exception.

The extracted formulary segments are presented as product listings with Drug Tier and Requirements/Limits flags; they do not contain a separate exclusions section. In other words, within the cited chunks there are no explicit exclusions listed — non‑coverage is primarily implied when a drug is absent from the Drug List rather than by named exclusion rules in these chunks.

The document excerpts show product lines annotated with tier and requirement flags but do not contain separate clinical exclusion rules in the cited chunks. There are no explicit clinical exclusions stated in these chunks; coverage limitations are conveyed by per‑product annotations such as PA, QL, SP, or AC rather than by standalone clinical exclusion statements.

The listed entries in these chunks are formulary lines with Drug Tier and Requirements/Limits annotations. They do not set out clinical coverage criteria (for example, specific diagnosis, prior‑therapy failure, or lab thresholds). Therefore, in the cited material there are no explicit clinical coverage criteria

The document extract conveys coverage stance via Drug Tier and Requirements/Limits fields and per‑product QL/PA/SP annotations, but it does not include a medical‑necessity decision algorithm in these chunks. There are no explicit medical necessity criteria described here; providers should follow the PA process and supply supporting clinical documentation when a PA is required.

Dispensing and quantity limits are enforced at claim adjudication. The plan notes that dispensed quantities beyond stated dispensing/quantity limits may be denied, and for certain controlled substances state law may prohibit coverage if the dispensed quantity exceeds the limit; in such cases the member would be responsible for the full cost of the excess medication. Providers should confirm per‑product QL values and follow prior authorization procedures when requesting quantities beyond listed limits.

Within the cited chunks there are no lines that explicitly state 'not medically necessary' determinations for specific clinical scenarios. The document communicates management via per‑product flags (e.g., PA, QL, SP) but does not include named 'not medically necessary' rulings in these excerpts.

The segments reviewed do not list specific conditions or situations labeled as 'not medically necessary.' Coverage is determined by whether a drug is on the Drug List and by the product's Requirements/Limits entries; explicit non‑medical‑necessity statements are not present in these chunks.

Specialty drugs are handled differently from standard retail medications: they may be oral, topical, or injectable and can be either self‑administered or provider‑administered. Provider‑administered products may fall under the medical benefit rather than the pharmacy benefit. The plan selects drugs for the list based on committee review considering safety, efficacy, cost, and FDA regulation. For specialty products the formulary uses annotations such as SP (specialty pharmacy), PA (prior authorization), and QL (quantity limits) to indicate additional management, and some specialty products will require dispensing through a specialty pharmacy or infusion/clinic setting as indicated.